Source: Annual Congress 2001 - Pulmonary hypertension: effect of iloprost
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Nikkho, W. Seeger, R. Baumgartner, J. Behr, M. Borst, R. Ewert, H. Ghofrani, M. Höper, A. Meyer, H. Siedentop, E. Spiekerkoetter, H. Wilkens, J. Winkler, H. Olschewski (Berlin, Giessen, Germany). One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension. Eur Respir J 2001; 16: Suppl. 31, 2164

Member's Comments

No comment yet.

Related content which might interest you: Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 18: 247 Year: 2001 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 1334-1335 Year: 2001 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 323s Year: 2001 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Intravenous iloprost as "rescue therapy" in patients with severe primary pulmonary hypertension deteriorating while on chronic aerosolized iloprost therapy Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004 Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 132-137 Year: 2009 Inhaled iloprost for the treatment of pulmonary hypertension Source: Eur Respir Rev 2009; 18: 29-34 Year: 2009 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005 Sildenafil and aerolized iloprost treatment in two cases with primary pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 520s Year: 2005 Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Experience with inhaled iloprost in paediatric pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006